Reid K, Surridge D H, Morales A, Condra M, Harris C, Owen J, Fenemore J
Lancet. 1987 Aug 22;2(8556):421-3. doi: 10.1016/s0140-6736(87)90958-5.
48 subjects meeting strict diagnostic criteria for psychogenic impotence took part in a 10 week placebo-controlled, double-blind, partial crossover trial of yohimbine (18 mg a day) for restoring erectile function. At the end of the first arm of the trial 62% of the yohimbine group and 16% of the placebo group reported some improvement in sexual function (chi 2 = 10.41, df = 2, p less than 0.05). 21% of the originally placebo-treated group noticed some improvement over pre-treatment levels when they were put on yohimbine in the second arm of the trial. Overall 46% of those who received yohimbine reported a positive response to the drug, a response rate very similar to that observed in a previous study of patients with organic impotence. Response to yohimbine thus seems to be unrelated to current groupings of the cause of impotence. Yohimbine is a safe treatment for psychogenic impotence that seems to be as effective as sex and marital therapy for restoring satisfactory sexual functioning.
48名符合心因性阳痿严格诊断标准的受试者参与了一项为期10周的关于育亨宾（每日18毫克）恢复勃起功能的安慰剂对照、双盲、部分交叉试验。在试验的第一阶段结束时，育亨宾组62%的受试者和安慰剂组16%的受试者报告性功能有一定改善（卡方 = 10.41，自由度 = 2，p < 0.05）。在试验的第二阶段，最初接受安慰剂治疗的组中有21%的受试者在服用育亨宾后性功能较治疗前有所改善。总体而言，接受育亨宾治疗的受试者中有46%报告对该药物有阳性反应，这一反应率与先前一项关于器质性阳痿患者的研究中观察到的反应率非常相似。因此，对育亨宾的反应似乎与目前阳痿病因的分类无关。育亨宾是一种治疗心因性阳痿的安全药物，在恢复满意性功能方面似乎与性治疗和婚姻治疗同样有效。
